Aurobindo Pharma is accelerating its antibiotic production strategy with significant capacity expansion plans. The company expects its Penicillin-G facility in Andhra Pradesh to produce over 10,000 metric tonnes annually within the next 12 months, with ultimate capacity reaching 15,000 metric tonnes per annum. The CFO emphasized that yield levels are improving consistently, positioning the facility to deliver meaningful profitability gains. Additionally, Aurobindo's China-based manufacturing plant is progressing toward EBITDA break-even in Q4 and is expected to contribute substantially to bottom-line earnings next year. The government's one-year relaxation on minimum import prices for key antibiotics represents a strategic catalyst for the company, supporting India's self-reliance in pharmaceutical manufacturing while reducing supply disruption risks and strengthening domestic API produc
